Welcome to our dedicated page for SCYNEXIS news (Ticker: SCYX), a resource for investors and traders seeking the latest updates and insights on SCYNEXIS stock.
SCYNEXIS, Inc. develops therapies for severe rare diseases and difficult-to-treat fungal infections. The company’s updates center on SCY-770, a clinical-stage oral direct AMPK activator for autosomal dominant polycystic kidney disease, and SCY-247, a second-generation triterpenoid antifungal therapy in development for invasive candidiasis and prophylaxis of invasive fungal disease.
SCYNEXIS news also covers its fungerp antifungal platform, FDA designations for SCY-247, scientific presentations, financial results, and corporate actions. The company has licensed ibrexafungerp, including BREXAFEMME® for vulvovaginal candidiasis and reduction in recurrent vulvovaginal candidiasis, to GSK, making collaboration and license-agreement updates a recurring disclosure theme.
SCYNEXIS (SCYX) appointed Sanjay Subramanian, MBA, as Chief Financial Officer effective September 9, 2026, and announced the concurrent retirement of CFO Ivor Macleod, who will remain through October 9, 2026 to support the transition.
Subramanian brings more than 20 years of finance, capital markets, business development and operational leadership experience in biotechnology, pharmaceuticals and healthcare, including CFO roles at Inozyme Pharma and Ocugen and finance leadership positions at Aralez Pharmaceuticals, Bausch Health Companies and General Motors. He led Inozyme Pharma’s acquisition by BioMarin Pharmaceutical. In connection with his appointment, on September 9, 2026 he received an option to purchase 100,000 SCYNEXIS shares at an exercise price of $4.91 per share, with a ten-year term and four-year vesting schedule, granted under the SCYNEXIS 2015 Inducement Award Plan pursuant to Nasdaq Listing Rule 5635(c)(4).
SCYNEXIS (Nasdaq: SCYX), a clinical-stage biotechnology company, announced participation in two upcoming investor conferences in New York City. The company will join a fireside chat at the 12th Cantor Global Healthcare Conference on Friday, September 11, 2026, at 9:45 a.m. ET, which will be webcast live with a replay available for 90 days. SCYNEXIS will also take part in 1x1 investor meetings at the H.C. Wainwright 28th Annual Global Investment Conference from September 14–16, 2026.
SCYNEXIS (Nasdaq: SCYX) granted an inducement equity award to a new Senior Director effective August 24, 2026, under Nasdaq Listing Rule 5635(c)(4). The grant was made pursuant to the company’s 2015 Inducement Award Plan, as amended, to encourage the employee’s acceptance of employment.
The award consists of stock options to purchase 20,000 shares of common stock at an exercise price of $5.26 per share, equal to the closing trading price on the grant date. The options have a ten-year term, with 25% vesting after one year and the remaining shares vesting in equal monthly installments over the following 36 months, subject to continued service.
SCYNEXIS (NASDAQ: SCYX) reported second quarter 2026 results and a corporate update. License revenue was $0.2 million, while operating expenses totaled $8.0 million, leading to a loss from operations of $7.8 million. Net income for the quarter was $7.4 million, driven largely by $15.2 million in other income, including a $14.2 million fair value gain on warrant liabilities.
R&D expenses declined 46% year over year to $3.9 million. The company ended June 30, 2026 with $71.1 million in cash, cash equivalents and investments, supported by a $36.9 million private placement completed in April; SCYNEXIS expects this to fund operations into 2029. The company initiated a Phase 1 study of SCY-770 for ADPKD with topline data expected in Q3 2026 and plans a Phase 2 proof-of-concept trial in Q4 2026. Dosing was completed in a Phase 1 study of IV antifungal SCY-247, with topline data also expected in Q3 2026. According to SCYNEXIS, a BREXAFEMME relaunch by GSK could trigger up to $146 million in annual net sales milestones plus low- to mid-single-digit net royalties.
SCYNEXIS (NASDAQ: SCYX) has initiated a Phase 1 study of SCY-770, a first-in-class, oral AMPK activator for autosomal dominant polycystic kidney disease (ADPKD). The study in healthy participants will assess food effect and pharmacokinetics across multiple dosing regimens, with topline data expected in Q3 2026.
Results are intended to support a Phase 2 proof-of-concept trial in ADPKD targeted for Q4 2026. SCY-770 has Orphan Drug Designation from the FDA and, according to SCYNEXIS, has shown supportive preclinical data and a well-characterized safety profile in over 270 prior clinical trial participants.
SCYNEXIS (NASDAQ: SCYX) approved a 1-for-8 reverse stock split of its common stock, effective 4:05 p.m. ET on May 29, 2026. Trading on a split-adjusted basis begins June 1, 2026 under the existing symbol with a new CUSIP.
The split aims to satisfy Nasdaq’s minimum bid price requirement and reduces authorized shares from 150 million to 18.75 million and outstanding shares from about 79.5 million to 9.9 million. Fractional shares will be paid in cash.
SCYNEXIS (NASDAQ:SCYX) reported Q1 2026 results and a major pipeline expansion. The company acquired SCY-770, an oral AMPK activator for ADPKD with FDA Orphan Drug designation, and plans a Phase 2 study starting Q4 2026 with early efficacy data expected in H2 2027.
SCYNEXIS advanced antifungal SCY-247, completed oral Phase 1, began IV Phase 1 dosing, and opened an expanded access program. A March private placement delivered about $37.2 million net, supporting a cash runway to mid-2029. GSK’s planned BREXAFEMME relaunch could generate up to approximately $146 million in annual net sales milestones.
SCYNEXIS (Nasdaq: SCYX) announced inducement equity awards approved April 30, 2026 for a newly hired Vice President. The grants include stock options for 125,000 shares at an exercise price of $0.93 and 20,000 RSUs.
Options vest over four years starting April 13, 2026; RSUs vest in three equal annual installments beginning June 15, 2026. Awards were granted under the company’s 2015 Inducement Award Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
Poxel sold clinical-stage AMPK activator PXL770 (to be renamed SCY-770) to Scynexis (NASDAQ: SCYX) for total consideration of up to $196 million, including an $8 million upfront payment and up to $188 million in milestone payments. PXL770 holds FDA orphan drug designation and patent protection through at least 2041. A Phase 2 ADPKD proof-of-concept study is expected to start in Q4 2026 with a first efficacy readout in H2 2027. IPF will receive 75% of proceeds to repay debt, with limited amounts retained for Poxel liquidity.
SCYNEXIS (NASDAQ: SCYX) entered a private placement expected to close on or about April 1, 2026, generating approximately $40.0 million upfront and up to $52.2 million more if Common Warrants are fully exercised, subject to stockholder approval.
The company will issue 34,750,000 common shares, 8,750,000 pre-funded warrants and accompanying Common Warrants for an aggregate of 43,500,000 warrants; combined prices were $0.92 and $0.9199. The financing extends cash runway into mid-2029 and includes institutional investors and CEO participation.